The Clinical Characteristics of Different SARS-COV-2 Variants in South Kalimantan
DOI:
https://doi.org/10.18196/mmjkk.v23i2.15009Keywords:
COVID-19, delta, probable omicron, Non-VOC, clinical characteristicsAbstract
COVID-19 has numerous variations as a result of ongoing mutations. Presumably, each variant has its particular clinical characteristic. We present three cases of COVID-19 patients, each with a Non-VOC, delta variant, and probable omicron variant with equal severity and few comorbidities for uniform comparison. All three cases had common COVID-19 symptoms. However, anosmia or ageusia was not found in the probable Omicron case, and the onset was shorter. Infiltrates in chest X-rays were found in all three cases. Laboratory examination showed altered inflammatory markers, transaminitis, and electrolyte imbalance. The standard therapy was given to all patients. However, additional therapies, tocilizumab, IVIG, and plasma convalescent, were given only to Non-VOC and delta variants cases. Non-VOC and delta cases were discharged for self-isolation in 11 and 15 days of treatment. Meanwhile, in the probable Omicron variant, the patient was discharged by his will after being treated for eight days.References
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022 [cited 2022 Feb 12]. https://covid19.who.int/
Das JK, Roy S. A study on non-synonymous mutational patterns in structural proteins of SARS-CoV-2. Genome. 2021;1–14. http://dx.doi.org/10.1139/gen-2020-0157
World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 2022 [cited 2022 Feb 12]. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M, et al. Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the Alpha variant in both unvaccinated and vaccinated individuals. bioRxiv. 2021. http://dx.doi.org/10.1101/2021.08.15.21262077
Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe. 2021;2(12):e666–75. http://dx.doi.org/10.1016/s2666-5247(21)00219-6
Fibriani A, Stephanie R, Alfiantie AA, Siregar ALF, Pradani GAP, Yamahoki N, et al. Analysis of SARS-CoV-2 genomes from west java, Indonesia. Viruses. 2021;13(10):2097. http://dx.doi.org/10.3390/v13102097
Kadir A, Deby S, Muhammad A. A Systematic Review of Omicron Outbreak in Indonesia : A Case Record and How Country is Weathering the New Variant of COVID-19. 2022;09(01):364–73.
Khan NA, Al-Thani H, El-Menyar A. The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues. Travel Med Infect Dis. 2022;45(102246):102246. http://dx.doi.org/10.1016/j.tmaid.2021.102246
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049–57. http://dx.doi.org/10.18632/aging.103000
Alam MR, Kabir MR, Reza S. Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey. Prev Med Rep. 2021;21(101319):101319. http://dx.doi.org/10.1016/j.pmedr.2021.101319
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–8. http://dx.doi.org/10.1007/s00392-020-01626-9
Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853–62. http://dx.doi.org/10.1016/s2213-2600(20)30316-7
Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, immunity, and COVID-19: How age influences the host immune response to Coronavirus infections? Front Physiol. 2021;11. http://dx.doi.org/10.3389/fphys.2020.571416
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. http://dx.doi.org/10.1001/jama.2020.1585
Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020;21(100331):100331. http://dx.doi.org/10.1016/j.eclinm.2020.100331
Pyar KP, Hla SA, Aung SM, Wunn D, Htet Aung ZN, Maung NL, et al. Breakthrough infection among fully vaccinated physicians working in COVID-19 treatment centers; Prevalence, presenting symptoms, co-morbidities and outcome in the third wave of epidemics in Myanmar. J Biomed Res Environ Sci. 2021;2(8):721–30. http://dx.doi.org/10.37871/jbres1303
Mulazim P, Bukhari H. Recently Discovered Omicron : Fifth Wave of Pandemic in Pakistan. What Strategies Can be adopted to Control its Spread ? Vol. 16, JIIMC. 2021 [cited 2022 Feb 17]. p. 212–4. https://journals.riphah.edu.pk/index.php/jiimc/article/view/1164
Armando F, Beythien G, Kaiser F, Allnoch L, Heydemann L, Rosiak M, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus). 2022 Feb 1; http://dx.doi.org/10.21203/rs.3.rs-1315280/v1
Sohrabi MR, Amin R, Maher A, Bahadorimonfared A, Janbazi S, Hannani K, et al. Sociodemographic determinants and clinical risk factors associated with COVID-19 severity: a cross-sectional analysis of over 200,000 patients in Tehran, Iran. BMC Infect Dis. 2021;21(1). http://dx.doi.org/10.1186/s12879-021-06179-4
Moradi EV, Teimouri A, Rezaee R, Morovatdar N, Foroughian M, Layegh P, et al. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. Am J Emerg Med. 2021;40:11–4. http://dx.doi.org/10.1016/j.ajem.2020.12.003
Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis. Am J Emerg Med. 2021;39:173–9. http://dx.doi.org/10.1016/j.ajem.2020.09.018
Taj S, kashif A, Arzinda Fatima S, Imran S, Lone A, Ahmed Q. Role of hematological parameters in the stratification of COVID-19 disease severity. Ann Med Surg (Lond). 2021;62:68–72. http://dx.doi.org/10.1016/j.amsu.2020.12.035
Pranata R, Lim MA, Yonas E, Huang I, Nasution SA, Setiati S, et al. Thrombocytopenia as a prognostic marker in COVID-19 patients: diagnostic test accuracy meta-analysis. Epidemiol Infect. 2021;149(e40). http://dx.doi.org/10.1017/s0950268821000236
Anirvan P, Narain S, Hajizadeh N, . Aloor FZ, Singh SP, Satapathy SK. Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): untangling the knots. Eur J Gastroenterol Hepatol. 2021;33(1S):e42–9. http://dx.doi.org/10.1097/meg.0000000000002034
Vadiraj PK, Thareja S, Raman N, Karantha SC, Jayaraman M, Vardhan V. Does Raised Transaminases Predict Severity and Mortality in Patients with COVID 19? J Clin Exp Hepatol. 2022;12(4):1114–23. http://dx.doi.org/10.1016/j.jceh.2022.01.004
Pourfridoni M, Abbasnia SM, Shafaei F, Razaviyan J, Heidari-Soureshjani R. Fluid and Electrolyte Disturbances in COVID-19 and Their Complications. Cavalcanti Rolla V, editor. Biomed Res Int. 2021;2021:1–5. http://dx.doi.org/10.1155/2021/6667047
PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman Tata Laksana COVID-19. 4th ed. 2022.
Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. International Journal of Biological Sciences [Internet]. 2021;17(6):1530–7. Available from: http://dx.doi.org/10.7150/ijbs.58695
Rahmawaty D, Nadia Muslimah Annisa, Haryati. Hemostatic Factors and Its Correlation with Outcomes of COVID-19 Confirmed Patients in Ulin Regional Hospital Banjarmasin. ACI (Acta Cardiol Indones). 2021;7(2):7. http://dx.doi.org/10.22146/jaci.v7i2.1241
Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1). http://dx.doi.org/10.1186/s12967-020-02339-3
Herth FJF, Sakoulas G, Haddad F. Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series. Respiration. 2020;99(12):1145–53. http://dx.doi.org/10.1159/000511376
Huang S, Shen C, Xia C, Huang X, Fu Y, Tian L. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China. Med Sci Monit. 2020;27. http://dx.doi.org/10.12659/msm.928755
Downloads
Additional Files
Published
Issue
Section
License
Copyright
Authors retain copyright and grant Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) the right of first publication with the work simultaneously licensed under an Attribution 4.0 International (CC BY 4.0) that allows others to remix, adapt and build upon the work with an acknowledgment of the work's authorship and of the initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
Authors are permitted to copy and redistribute the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
License
Articles published in the Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) are licensed under an Attribution 4.0 International (CC BY 4.0) license. You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
This license is acceptable for Free Cultural Works. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
